AEON Biopharma, Inc. Class A (AEON)

The company's stock price experienced a significant decline of 97.47% between December 30, 2024, and December 29, 2025, and decreased by 97.50% over the last 12 months. In November 2025, AEON reported its Q3 results, which included positive analytical biosimilarity data for ABP-450, and scheduled an FDA Type 2a meeting for November 19, 2025, which was later rescheduled to January 21, 2026. The company also announced a $6 million PIPE financing and a proposed Daewoong note exchange. In December 2025, AEON announced the execution of an exchange agreement with Daewoong and reported inducement grants. In January 2026, AEON Biopharma released an updated investor presentation and strengthened its financial position through an underwritten public offering, raising $20.0 million in gross proceeds.

There is no specific information available in the provided search results indicating demand seasonality for AEON Biopharma's products or services. The company's focus on therapeutic botulinum toxins for medical conditions does not inherently suggest seasonal demand patterns.

AEON Biopharma is a clinical-stage biopharmaceutical company focused on developing therapeutic applications of botulinum toxins, operating within the Health Care sector, specifically in the Biotechnology and Pharmaceuticals & Biotech industries, with a focus on Drug Discovery. The company's core business revolves around the research, development, and commercialization of novel biopharmaceutical products, with its primary product, ABP-450, being developed for therapeutic indications such as cervical dystonia, chronic and episodic migraine, gastroparesis, and post-traumatic stress disorder. AEON is pursuing a biosimilar regulatory pathway for ABP-450, aiming for accelerated and full-label access to the U.S. therapeutic neurotoxin market, using BOTOX as the reference product. ABP-450 is manufactured by Daewoong Pharmaceutical Co., LTD.

AEON Biopharma, Inc. is headquartered in Irvine, California, United States. The company holds exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. ABP-450 is already approved as a biosimilar in India, Mexico, and the Philippines.

The provided search results do not contain explicit information regarding AEON Biopharma's brand reputation in the past year. However, the significant decline in stock price and the mention of major setbacks for its lead drug candidate, including a Phase 2 trial for migraines not meeting its primary endpoint in June 2024, could indirectly impact public and investor perception. The company's efforts to secure financing, reduce debt, and advance its biosimilar program, along with positive biosimilarity data, suggest ongoing efforts to build confidence.

AEON Biopharma's ownership is a mix of institutional shareholders, insiders, and retail investors. Approximately 10.01% to 22.78% of the company's stock is held by institutional investors, while insiders hold between 0.90% and 230.95%. Major institutional owners include Dauntless Investment Group, LLC, Vanguard Group Inc., and Geode Capital Management, Llc. Major individual and insider owners include Priveterra Sponsor LLC, Daewoong Co Ltd, and Robert J. Palmisano. Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 965.9%.